If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.
A recent CME course using Facebook Live generated 34,000 views and 600 comments.
Drugmakers can do a better job of organizing dosing information, safety information, and clinical data on their brand websites, a new survey found.
Jeanne Martel, president and partner at ClinicalMind, highlights her company's vision and role in communication and technology with MM&M's Jaimy Lee. This video was sponsored by ClinicalMind.
With the acquisition of VR developer BioLucid, Sharecare hopes to use empathy to encourage behavior change.
Sharecare acquires virtual-reality developer; Novo Nordisk to cut 1,000 jobs; the FDA approves Medtronic's automated insulin pump
Following print's best year since 2011, it's time to rewrite those journal-advertising obituaries. Medical-surgical print journal spending in 2015 was up 8.4% to $372 million.
Here are the brands and companies that advertised the most on professional ads in 2015.
The deal combines two of Merck's wholly owned subsidiaries.
The website is a joint effort between Merck and The Lancet.
The agency made good on a pledge to expand Bad Ad with a web-based CME course and case studies representing common problems.
Some providers of CME are getting better at complying with accreditation criteria, data show, yet many are still struggling to meet a stricter set of requirements.
Pharma's med-ed cut was its fifth in a row. But other income surged, filling the void as the funding picture for CME continued to even out.
With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
The estimated cost savings for only 10% of participants changing their practice is somewhere in the million-dollar range, according to a study.
Boehringer Ingelheim and Eli Lilly rolled out a pre-launch SGLT campaign that breaks ranks with branding for J&J's SGLT2 inhibitor Invokana.
Medical science liaisons will educate nuclear-medicine clinicians as part of the launch of a new Navidea diagnostic agent for use in breast and skin cancer.
What will become of Dollars for Docs after the Sunshine provisions go into effect? We asked Charles Ornstein, who told us what's next for the project.
Gift bans or no, students still connect with drug companies, a study has found.
The med-ed company is buying Amazing Charts, a tie-up the firms say will enable them to deliver customized education to physicians and then assess the patient-level impact.
Only 35% of physicians are aware of the FDA's class-wide safety plan for certain opioids, a survey showed, suggesting an awareness challenge as the plan gets under way.
A new online medical contest is progressing from the diagnosis of minor ailments to cancer screening.
Allergan removed records from its website that had detailed payments made to doctors from the middle of 2010 through first-half 2011.
Those who produce and fund certified medical education acknowledge that conflict of interest is one issue that seems to constantly crop up. But while conflict is inevitable, bias doesn't have to be, they insist in a new video.
Pfizer is changing the way it funds medical education to make smarter use of a shrinking pool of funds and to enhance the impact of activities it supports.
It probably won't have the same ability to tap industry for support, but a new med-ed center at Stanford has some other interesting parallels with the school's CME program.
The ACCME awarded provisional two-year accreditation to Lighthouse Learning, the educational content provider which develops and sells CME curricula without accepting commercial funding.
Corporate logos may still appear in CME commercial support disclosures, ACCME said, after a majority of respondents expressed disapproval of its proposal to ban them.
The drug industry's backing of certified CME fell for a third straight year, as registration fees and other income surged, just-released data from ACCME show.
In a sign of industry's ongoing desire to broaden its CME funding outlook, a couple of recently supported educational programs by Pfizer aim to foster practice-based improvement as they seek to advance the science of CME.